Dogwood Therapeutics highlights Halneuron Phase 2b data readout timeline for chemotherapy-induced neuropathic pain program

Reuters2026/09/04 14:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Dogwood Therapeutics investor presentation outlined a non-opioid pain pipeline led by Halneuron injection for chemotherapy-induced neuropathic pain.
Halneuron Phase 2b data readout targeted for fall; FDA end-of-Phase 2 submission planned for Q4.
Program positioned around Nav1.7 sodium-channel blockade using tetrodotoxin, designed for peripheral pain modulation without central nervous system effects.
Cash totaled USD 13.2 million on a March 31 pro forma basis; shares outstanding listed as 33,553.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief on September 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Dogwood Therapeutics highlights Halneuron Phase 2b data readout timeline for chemotherapy-induced neuropathic pain program

You may also like

Crypto prices